Epigenetic remodeling via HDAC6 inhibition amplifies anti-tumoral immune responses in myeloid leukemia cells

Huang HT, Figueroa ME. Epigenetic deregulation in myeloid malignancies. Blood. 2021;138:613–24.

Google Scholar 

Wang P, Wang Z, Liu J. Role of HDACs in normal and malignant hematopoiesis. Mol Cancer. 2020;19:5.

Google Scholar 

Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–74.

Google Scholar 

Zhang J, Gao X, Yu L. Roles of histone deacetylases in acute myeloid leukemia with fusion proteins. Front Oncol. 2021;11:741746.

Google Scholar 

Abaza YM, Kadia TM, Jabbour EJ, Konopleva MY, Borthakur G, Ferrajoli A, et al. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer. 2017;123:4851–9.

Google Scholar 

Pommert L, Schafer ES, Malvar J, Gossai N, Florendo E, Pulakanti K, et al. Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. Am J Hematol. 2022;97:613–22.

Google Scholar 

Karol SE, Cooper TM, Mead PE, Crews KR, Panetta JC, Alexander TB, et al. Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia. Cancer. 2020;126:4800–5.

Google Scholar 

San Jose-Eneriz E, Gimenez-Camino N, Agirre X, Prosper F. HDAC inhibitors in acute myeloid leukemia. Cancers. 2019;11:1794.

Google Scholar 

Hosseini MS, Sanaat Z, Akbarzadeh MA, Vaez-Gharamaleki Y, Akbarzadeh M. Histone deacetylase inhibitors for leukemia treatment: current status and future directions. Eur J Med Res. 2024;29:514.

Google Scholar 

Shah RR. Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology. Drug Saf. 2019;42:235–45.

Google Scholar 

Chen J, Ren JJ, Cai J, Wang X. Efficacy and safety of HDACIs in the treatment of metastatic or unresectable renal cell carcinoma with a clear cell phenotype: a systematic review and meta-analysis. Medicine. 2021;100:e26788.

Google Scholar 

Gryder BE, Sodji QH, Oyelere AK. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem. 2012;4:505–24.

Google Scholar 

Suraweera A, O’Byrne KJ, Richard DJ. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Front Oncol. 2018;8:92.

Google Scholar 

Zhou M, Yuan M, Zhang M, Lei C, Aras O, Zhang X, et al. Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy. Eur J Med Chem. 2021;226:113825.

Google Scholar 

Li T, Zhang C, Hassan S, Liu X, Song F, Chen K, et al. Histone deacetylase 6 in cancer. J Hematol Oncol. 2018;11:111.

Google Scholar 

Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, et al. HDAC6 is a microtubule-associated deacetylase. Nature. 2002;417:455–8.

Google Scholar 

Zhang X, Yuan Z, Zhang Y, Yong S, Salas-Burgos A, Koomen J, et al. HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell. 2007;27:197–213.

Google Scholar 

Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell. 2005;18:601–7.

Google Scholar 

Ryu HW, Shin DH, Lee DH, Choi J, Han G, Lee KY, et al. HDAC6 deacetylates p53 at lysines 381/382 and differentially coordinates p53-induced apoptosis. Cancer Lett. 2017;391:162–71.

Google Scholar 

Zhang Y, Kwon S, Yamaguchi T, Cubizolles F, Rousseaux S, Kneissel M, et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol. 2008;28:1688–701.

Google Scholar 

Maharaj K, Powers JJ, Achille A, Deng S, Fonseca R, Pabon-Saldana M, et al. Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia. Blood Adv. 2018;2:3012–24.

Google Scholar 

Losson H, Schnekenburger M, Dicato M, Diederich M. HDAC6-an emerging target against chronic myeloid leukemia?. Cancers. 2020;12:318.

Google Scholar 

Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT, et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia. 2005;19:1751–9.

Google Scholar 

Lernoux M, Schnekenburger M, Losson H, Vermeulen K, Hahn H, Gerard D, et al. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells. Clin Epigenetics. 2020;12:69.

Google Scholar 

Bamodu OA, Kuo KT, Yuan LP, Cheng WH, Lee WH, Ho YS, et al. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1. Exp Cell Res. 2018;370:519–30.

Google Scholar 

Pezzotta A, Gentile I, Genovese D, Totaro MG, Battaglia C, Leung AY, et al. HDAC6 inhibition decreases leukemic stem cell expansion driven by Hedgehog hyperactivation by restoring primary ciliogenesis. Pharm Res. 2022;183:106378.

Google Scholar 

Hackanson B, Rimmele L, Benkisser M, Abdelkarim M, Fliegauf M, Jung M, et al. HDAC6 as a target for antileukemic drugs in acute myeloid leukemia. Leuk Res. 2012;36:1055–62.

Google Scholar 

Reßing N, Sönnichsen M, Osko JD, Schöler A, Schliehe-Diecks J, Skerhut A, et al. Multicomponent synthesis, binding mode, and structure-activity relationship of selective histone deacetylase 6 (HDAC6) inhibitors with bifurcated capping groups. J Med Chem. 2020;63:10339–51.

Google Scholar 

Reßing N, Schliehe-Diecks J, Watson PR, Sönnichsen M, Cragin AD, Schöler A, et al. Development of fluorinated peptoid-based histone deacetylase (HDAC) inhibitors for therapy-resistant acute leukemia. J Med Chem. 2022;65:15457–72.

Google Scholar 

Depetter Y, Geurs S, De Vreese R, Goethals S, Vandoorn E, Laevens A, et al. Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models. Int J Cancer. 2019;145:735–47.

Google Scholar 

Bolouri H, Farrar JE, Triche T Jr, Ries RE, Lim EL, Alonzo TA, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24:103–12.

Google Scholar 

Gyorffy B. Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer. Geroscience. 2023;45:1889–98.

Google Scholar 

Vogl DT, Raje N, Jagannath S, Richardson P, Hari P, Orlowski R, et al. Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. Clin Cancer Res. 2017;23:3307–15.

Google Scholar 

Yee AJ, Bensinger WI, Supko JG, Voorhees PM, Berdeja JG, Richardson PG, et al. Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. Lancet Oncol. 2016;17:1569–78.

Google Scholar 

Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W, et al. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell. 2009;138:1019–31.

Google Scholar 

Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell. 2003;115:727–38.

Google Scholar 

Wang R, Tan J, Chen T, Han H, Tian R, Tan Y, et al. ATP13A2 facilitates HDAC6 recruitment to lysosome to promote autophagosome-lysosome fusion. J Cell Biol. 2019;218:267–84.

Google Scholar 

Bobrowicz M, Dwojak M, Pyrzynska B, Stachura J, Muchowicz A, Berthel E, et al. HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. Blood. 2017;130:1628–38.

Google Scholar 

Campomenosi P, Mortara L, Bassani B, Valli R, Porta G, Bruno A. The potential role of the T2 ribonucleases in TME-based cancer therapy. Biomedicines. 2023;11:2160.

Google Scholar 

Wu L, Xu Y, Zhao H, Li Y. RNase T2 in inflammation and cancer: immunological and biological views. Front Immunol. 2020;11:1554.

Google Scholar 

Acquati F, Lualdi M, Bertilaccio S, Monti L, Turconi G, Fabbri M, et al. Loss of function of Ribonuclease T2, an ancient and phylogenetically conserved RNase, plays a crucial role in ovarian tumorigenesis. Proc Natl Acad Sci USA. 2013;110:8140–5.

Google Scholar 

Acquati F, Mortara L, De Vito A, Baci D, Albini A, Cippitelli M, et al. Innate immune response regulation by the human RNASET2 tumor suppressor gene. Front Immunol. 2019;10:2587.

Google Scholar 

Mopin A, Driss V, Brinster C. A detailed protocol for characterizing the murine C1498 cell line and its associated leukemia mouse model. J Vis Exp. 2016;116:e54270.

Google Scholar 

Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003;281:65–78.

Google Scholar 

Namdar M, Perez G, Ngo L, Marks PA. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci USA. 2010;107:20003–8.

Google Scholar 

Jin J, Meng T, Yu Y, Wu S, Jiao CC, Song S, et al. Human HDAC6 senses valine abundancy to regulate DNA damage. Nature. 2025;637:215–23.

Google Scholar 

Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, et al. Acute myeloid leukaemia. Nat Rev Dis Prim. 2016;2:16010.

Google Scholar 

Umeda M, Ma J, Westover T, Ni Y, Song G, Maciaszek JL, et al. A new genomic framework to categorize pediatric acute myeloid leukemia. Nat Genet. 2024;56:281–93.

Google Scholar 

Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol. 2025;100:860–91.

Google Scholar 

Hu Z, Van Rooijen N, Yang YG. Macrophages prevent human red blood cell reconstitution in immunodeficient mice. Blood. 2011;118:5938–46.

Google Scholar 

Lee J-Y, Koga H, Kawaguchi Y, Tang W, Wong E, Gao Y-S, et al. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J. 2010;29:969–80.

Google Scholar 

Lee JY, Kawaguchi Y, Li M, Kapur M, Choi SJ, Kim HJ, et al. Uncoupling of protein aggregation and neurodegeneration in a mouse amyotrophic lateral sclerosis model. Neurodegener Dis. 2015;15:339–49.

Google Scholar 

Iwata A, Riley BE, Johnston JA, Kopito RR. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J Biol Chem. 2005;280:40282–92.

Google Scholar 

Zhan Y, Wang H, Zhang L, Pei F, Chen Z. HDAC6 regulates the fusion of autophagosome and lysosome to involve in odontoblast differentiation. Front Cell Dev Biol. 2020;8:605609.

Google Scholar 

Qu M, Zhang H, Cheng P, Wubshet AK, Yin X, Wang X, et al. Histone deacetylase 6’s function in viral infection, innate immunity, and disease: latest advances. Front Immunol. 2023;14:1216548.

Google Scholar 

Xu G, Niu L, Wang Y, Yang G, Zhu X, Yao Y, et al. HDAC6-dependent deacetylation of TAK1 enhances sIL-6R release to promote macrophage M2 polarization in colon cancer. Cell Death Dis. 2022;13:888.

Google Scholar 

Lin A, Giuliano CJ, Palladino A, John KM, Abramowicz C, Yuan ML. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci Transl Med. 2019;11:eaaw8412.

Google Scholar 

Medard G, Sheltzer JM. Ricolinostat is not a highly selective HDAC6 inhibitor. Nat Cancer. 2023;4:807–8.

Google Scholar 

Kovalovsky D, Noonepalle S, Suresh M, Kumar D, Berrigan M, Gajendran N, et al. The HDAC6 inhibitor AVS100 (SS208) induces a pro-inflammatory tumor microenvironment and potentiates immunotherapy. Sci Adv. 2024;10:eadp3687.

Google Scholar 

Jin J, Zhang H, Weyand CM, Goronzy JJ. Lysosomes in T cell immunity and aging. Front Aging. 2021;2:809539.

Google Scholar 

Adeegbe DO, Liu Y, Lizotte PH, Kamihara Y, Aref AR, Almonte C, et al. Synergistic immunostimulatory effects and therapeutic benefit of combined histone deacetylase and bromodomain inhibition in non-small cell lung cancer. Cancer Discov. 2017;7:852–67.

Google Scholar 

Bae J, Hideshima T, Tai YT, Song Y, Richardson P, Raje N, et al. Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. Leukemia. 2018;32:1932–47.

Google Scholar 

Vogt M, Dienstbier N, Schliehe-Diecks J, Scharov K, Tu JW, Gebing P, et al. Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells. Cell Death Dis. 2023;14:799.

Google Scholar 

Bhatia S, Diedrich D, Frieg B, Ahlert H, Stein S, Bopp B, et al. Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response. Blood. 2018;132:307–20.

Google Scholar 

Flumann R, Rehkamper T, Nieper P, Pfeiffer P, Holzem A, Klein S, et al. An autochthonous mouse model of Myd88- and BCL2-driven diffuse large B-cell lymphoma reveals actionable molecular vulnerabilities. Blood Cancer Discov. 2021;2:70–91.

Google Scholar 

Gebing P, Loizou S, Hansch S, Schliehe-Diecks J, Spory L, Stachura P, et al. A brain organoid/ALL coculture model reveals the AP-1 pathway as critically associated with CNS involvement of BCP-ALL. Blood Adv. 2024;8:4997–5011.

Google Scholar 

Stachura P, Liu W, Xu HC, Wlodarczyk A, Stencel O, Pandey P, et al. Unleashing T cell anti-tumor immunity: new potential for 5-Nonloxytryptamine as an agent mediating MHC-I upregulation in tumors. Mol Cancer. 2023;22:136.

Google Scholar 

Stachura P, Stencel O, Lu Z, Borkhardt A, Pandyra AA. Arenaviruses: old viruses present new solutions for cancer therapy. Front Immunol. 2023;14:1110522.

Google Scholar 

DepMap, Broad (2024). DepMap 24Q4 Public. Figshare+. Dataset. https://doi.org/10.25452/figshare.plus.27993248.v1.

McLeod C, Gout AM, Zhou X, Thrasher A, Rahbarinia D, Brady SW, et al. St. Jude Cloud: a pediatric cancer genomic data-sharing ecosystem. Cancer Discov. 2021;11:1082–99.

Google Scholar 

Dwivedi B, Mumme H, Satpathy S, Bhasin SS, Bhasin M. Survival Genie, a web platform for survival analysis across pediatric and adult cancers. Sci Rep. 2022;12:3069.

Google Scholar 

Drier Y, Sheffer M, Domany E. Pathway-based personalized analysis of cancer. Proc Natl Acad Sci USA. 2013;110:6388–93.

Google Scholar 

Muller-Dott S, Tsirvouli E, Vazquez M, Ramirez Flores RO, Badia IMP, Fallegger R, et al. Expanding the coverage of regulons from high-confidence prior knowledge for accurate estimation of transcription factor activities. Nucleic Acids Res. 2023;51:10934–49.

Google Scholar